By Counterforce Health Team in Pemazyre (pemigatinib) —

Myths vs. Facts: Getting Pemazyre (pemigatinib) Covered by Humana in Georgia

Quick Answer: Pemazyre (pemigatinib) is covered by Humana Medicare Advantage plans in Georgia with prior authorization and quantity limits. Common myths include believing all cancer drugs are automatically covered or that Medicare patients can't get financial help. The fastest path to approval: 1) Confirm FGFR2 fusion testing, 2) Submit complete PA with ophthalmology monitoring plan, 3) Contact IncyteCARES at 1-855-452-5234 for patient assistance if eligible.

Table of Contents

Why These Myths Persist

Getting specialty cancer drugs like Pemazyre (pemigatinib) covered by insurance can feel overwhelming, especially when you're dealing with a complex diagnosis like cholangiocarcinoma. Misinformation spreads quickly among patients and families who are trying to navigate unfamiliar territory while under stress.

The reality is that Humana—like most Medicare Advantage plans—has specific, documented requirements for Pemazyre coverage. Understanding these facts can save you weeks of delays and help you avoid common pitfalls that lead to denials.

Counterforce Health specializes in turning insurance denials into successful appeals by identifying the specific denial basis and crafting evidence-backed rebuttals aligned to each plan's own rules. Their platform helps patients and clinicians navigate the complex world of prior authorization requirements and appeals processes.

Common Myths Debunked

Myth 1: "If my oncologist prescribes Pemazyre, Humana has to cover it automatically"

Fact: Pemazyre requires prior authorization from Humana, even with a valid prescription. According to Humana's 2025 formulary, Pemazyre is covered but subject to utilization management including PA and quantity limits of 28 tablets per 28 days.

Myth 2: "Medicare patients can't get help with drug costs"

Fact: Starting in 2025, all Medicare Part D plans (including Medicare Advantage) have an annual out-of-pocket cap of $2,000 for prescription drugs. Additionally, Medicare patients may qualify for the IncyteCARES Patient Assistance Program if they meet income criteria, though they can't use copay cards.

Myth 3: "I need to try cheaper drugs first before Pemazyre will be covered"

Fact: Pemazyre doesn't typically require step therapy because it's indicated for patients with specific FGFR2 fusions or rearrangements. However, you must have documented evidence of this biomarker and be previously treated for your cholangiocarcinoma.

Myth 4: "Appeals rarely work for expensive cancer drugs"

Fact: While specific success rates for Humana aren't published, external reviews in Georgia often overturn 25-50% of denials when proper documentation is provided. Georgia's external review process is binding on insurers and free for consumers.

Myth 5: "I can start treatment while waiting for approval"

Fact: Unless you qualify for a temporary supply through IncyteCARES or pay out-of-pocket, you'll need to wait for approval. However, you can request expedited review (72-hour decision) if delays would jeopardize your health.

Myth 6: "All Humana plans have the same coverage rules"

Fact: While Medicare Advantage plans follow federal guidelines, specific formulary placement and PA criteria can vary slightly between Humana plan types. Always check your specific plan's formulary and coverage policies.

Myth 7: "Eye exams aren't really necessary for approval"

Fact: Ophthalmic monitoring is a critical FDA requirement for Pemazyre due to risk of retinal pigment epithelial detachment. Humana requires documentation of baseline eye exams and ongoing monitoring plans as part of their PA process.

What Actually Influences Approval

Understanding what Humana actually looks for can dramatically improve your chances of first-time approval:

Essential Documentation Requirements

FGFR2 Testing Results

  • Laboratory report confirming FGFR2 fusion or rearrangement from validated assay
  • Test must be from tumor tissue, not blood-based testing alone
  • Report should clearly state the specific alteration detected

Clinical History

  • Confirmed diagnosis of unresectable locally advanced or metastatic cholangiocarcinoma
  • Documentation of previous systemic therapy (Pemazyre is for previously treated patients)
  • Performance status and treatment goals

Monitoring Plans

  • Baseline comprehensive ophthalmologic examination with OCT
  • Plan for follow-up eye exams every 2 months for 6 months, then every 3 months
  • Laboratory monitoring plan for hyperphosphatemia

Coverage Decision Timeline

Step Timeline Action Required
PA Submission Day 1 Complete forms with all documentation
Humana Review 7 days standard May request additional information
Expedited Review 72 hours Available if delay poses health risk
Appeal (if denied) 65 days to file Internal reconsideration
External Review 60 days after internal appeal Georgia DOI process

Avoid These Critical Mistakes

1. Incomplete FGFR Testing Documentation

The most common reason for denial is submitting a PA without the actual laboratory report showing FGFR2 fusion. Don't just mention the test was positive—attach the full report.

2. Missing Ophthalmology Requirements

Failing to document baseline eye exam and monitoring plan leads to automatic denials. Schedule your ophthalmology consultation before submitting the PA.

3. Wrong Prior Authorization Forms

Using outdated forms or forms for different Humana plan types causes processing delays. Verify you're using the current form for your specific plan.

4. Inadequate Medical Necessity Letter

Generic letters that don't address Humana's specific criteria get denied. Your oncologist should specifically address:

  • FGFR2 alteration confirmation
  • Previous treatment history and outcomes
  • Why Pemazyre is medically necessary now
  • Monitoring and safety plans

5. Missing Appeal Deadlines

Georgia has strict timelines: 65 days to file internal appeals with Humana, then 60 days to request external review with the Georgia Department of Insurance. Missing these deadlines can eliminate your options.

Your 3-Step Action Plan

Step 1: Gather Your Documentation (Do This Week)

  • Request complete FGFR2 testing report from your pathology lab
  • Schedule comprehensive eye exam with ophthalmologist
  • Collect treatment history and previous therapy records
  • Verify your Humana plan details and formulary status

Step 2: Submit Complete Prior Authorization (Next Week)

  • Use current Humana PA forms for your specific plan type
  • Include all required documentation in first submission
  • Request expedited review if treatment delays pose health risks
  • Keep copies of everything submitted

Step 3: Prepare for Potential Denial (Ongoing)

  • Mark calendar with appeal deadlines (65 days for internal, 60 days for external)
  • Identify any missing documentation that could strengthen an appeal
  • Contact Counterforce Health if you receive a denial—they specialize in crafting targeted appeals that address specific denial reasons
  • Research patient assistance options through IncyteCARES

Resources and Support

Patient Assistance Programs

IncyteCARES Program

  • Phone: 1-855-452-5234 (Mon-Fri, 8AM-8PM ET)
  • Website: incytecares.com
  • Copay cards available for commercial insurance only
  • Patient assistance program for uninsured/underinsured, including Medicare patients who meet income criteria

Georgia Appeals Resources

Georgia Department of Insurance

  • Consumer Services: 1-800-656-2298
  • External review requests must be filed within 60 days
  • Process is free for consumers and binding on insurers

Humana Member Services

  • Check member portal for current PA forms and status
  • Request expedited reviews when medically necessary
  • Track appeal deadlines and requirements

Clinical Guidelines and Information

From Our Advocates: We've seen many patients successfully get Pemazyre covered after initial denials, especially when they had complete FGFR2 testing documentation and established ophthalmology monitoring. The key is often in the details—making sure every required piece of documentation is included in the first submission rather than waiting for the insurance company to request missing pieces.

Disclaimer: This information is for educational purposes only and is not medical advice. Always consult with your healthcare provider about your specific situation. Coverage policies and requirements may change. Verify current information with Humana and consult official sources linked throughout this article.

Sources & Further Reading:

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.